

REMARKS

Claims 10-18, 22-43 and 45-48 are pending. Claim 21 has been cancelled. Claim 48 has been directed to specific diseases described on page 2, lines 1-4, of the specification. Other minor editorial revisions have been made to some claims to improve their clarity. Accordingly, the Applicants do not believe that any new matter has been added.

Objection—Claim 21

This objection is moot in view of the cancellation of Claim 21.

Rejection—35 U.S.C. §112, first paragraph

Claim 48 was rejected under 35 U.S.C. 112, first paragraph, as lacking description or adequate enablement. The Applicants thank Examiner Coppins for the suggestion regarding revision of this claim. This language has been adopted based on the diseases disclosed at the top of page 2 of the specification. Accordingly, this rejection may now be withdrawn.

Information Disclosure Statement

The Applicants respectfully request that the Examiner fully acknowledge the documents cited on the information disclosure statement submitted February 14, 2002. Reference "AW", Z. Vejdelek et al., Chem. Abstracts 80, No. 7, page 279 (1974) has not been initialed. A copy of Form 1449 previously submitted on February 14, 2002 is attached to this response for the convenience of the Examiner.

CONCLUSION

In view of the above amendments and remarks, the Applicants respectfully submit that this application is now in condition for allowance. Notice to that effect is respectfully requested.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.
Norman F. Oblon

Customer Number

22850

Tel: (703) 413-3000
Fax: (703) 413 -2220
(OSMMN 06/04)


Thomas M. Cunningham
Attorney of Record
Registration No. 45,394

NFO/TMC:sjh